79002-45-2

Upstream product

• 621-84-1 O-benzyl carbamate 
• 6000-59-5 glyoxalic acid monohydrate 
• 4248-19-5 tert-butyl carbazate 
• 103711-22-4 α-(Isopropylthio)-Nα-(benzyloxycarbonyl)glycine 
• 501-53-1 benzyl chloroformate 
• 56-40-6 glycine 
• 3459-92-5 DBC 
• 563-96-2 2,2-dihydroxyacetic acid 
• 298-12-4 Glyoxilic acid 

Downstream Products

• 58486-94-5 N-Benzyloxycarbonyl-β,β-diacetylalanin 
• 127357-38-4 N-(benzyloxycarbonyl)-α-hydroxy-glycine methyl ester 
• 81639-11-4 N-benzyloxycarbonyl 2-<3-benzoselenophenyl>glycine 
• 127357-37-3 methyl 2-(benzyloxycarbonylamino)-2-methoxyacetate 
• 79002-44-1 Dl-α-benzyloxycarbonylamino-2,3-dihydro-5-benzo(b)furanyl acetic acid 
• 73101-08-3 N-(benzyloxycarbonyl)-3,4-(1',4'-dioxanyl)phenylglycine 
• 83026-98-6 N-carbobenzoxy-α-ethoxyglycine ethyl ester 
• 81639-09-0 N-benzyloxycarbonyl(4-methylseleno)phenylglycine 
• 66381-10-0 ((benzyloxy)carbonyl)-C²-tosylglycine 
• 66380-96-9 N-(benzyloxycarbonyl)-(alpha)-chloroglycinate 
• 42726-80-7 N-benzyloxycarbonyl-2-S-benzylthioglycine 
• 58486-95-6 N-Benzyloxycarbonyl-β-acetyl-β-benzoyl-alanin 
• 175667-02-4 N-carbobenzoxy-α-propoxyglycine propyl ester 
• 257933-01-0 2-(trimethylsilyl)ethyl α-hydroxy-N-(benzyloxycarbonyl)glycinate 

Relevant academic research and scientific papers

Preparation method of Wittig-Horner reagent

A preparation method of a Wittig-Horner reagent is disclosed. According to the preparation method of the Wittig-Horner reagent provided by the invention, a compound with a structure as shown in a formula (I) and a glyoxylic acid aqueous solution with a sp

Total Synthesis and Structure-Activity Relationships Study of Odilorhabdins, a New Class of Peptides Showing Potent Antibacterial Activity

The spread of antibiotic-resistant pathogens is a growing concern, and new families of antibacterials are desperately needed. Odilorhabdins are a new class of antibacterial compounds that bind to the bacterial ribosome and kill bacteria through inhibition

NOVEL PEPTIDE DERIVATIVES AND USES THEREOF

The invention provides for novel peptide derivatives and compositions comprising the same. The invention further provides methods of treatment comprising administering novel peptide derivatives and/or compositions comprising the same.

NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS

The invention relates to novel heteroaryl and heterocycle compounds of formula I and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of PI3K and for treating inflammatory and autoimmune diseases and cancer.

NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS

Provided are novel heteroaryl and heterocycle compounds of formula (I-1), (I-2) or (I-3) and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of PI3K and for treating inflammatory and autoimmune disorders diseases and cancer.

NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITIONS AND METHODS

The invention relates to novel heteroaryl and heterocycle compounds and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of PI3k and for treating inflammatory and autoimmune disorders diseases and cancer.

NOVEL HETEROARYL AND HETEROCYCLE COMPOUNDS, COMPOSITION AND METHODS THEREOF

Disclosed are novel heteroaryl and heterocycle compounds of formula I-1, I-2 or I-3 and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of PI3K and for treating inflammatory and autoimmune diseases and cancer.

BARETTIN AND DERIVATIVES THEREOF FOR MEDICAL USE, IN PARTICULAR FOR THE TREATMENT OF DISEASES RELATED TO OXIDATIVE STRESS OR INFLAMMATION, AND FOR PRESERVING OR WASHING ORGANS

The present invention relates to compounds of formula(I) herein, which includes barettin and derivatives thereof, or any pharmaceutically acceptable salt thereof for use as a medicament. Further the present invention relates to same compounds for use in t

SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS

The present invention relates to a series of substituted compounds having the general formula (I), including their ste reoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3. R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of N-benzyl 2-amino-2-(hetero)aromatic acetamides

N-Benzyl 2-acetamido-2-substituted acetamides, where the 2-substituent is a (hetero)aromatic moiety, are potent anticonvulsants. We report the synthesis and whole animal pharmacological evaluation of 16 analogues where the terminal 2-acetyl group was removed to give the corresponding primary amino acid derivatives (PAADs). Conversion to the PAAD structure led to a substantial drop in seizure protection in animal tests, demonstrating the importance of the N-acetyl moiety for anticonvulsant activity. However, several of the PAADs displayed notable pain-attenuating activities in a mouse model.